A prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in Atypical Hemolytic Uremic Syndrome patients

Trial Identifier: D7413R00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: December 2027
Study Completion Date: December 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anhui, China
China Beijing, China
China Chongqing, China
China Fujian, China
China Guangdong, China
China Guangxi, China
China Guizhou, China
China Hainan, China
China Hebei, China
China Henan, China
China Hong Kong, China
China Hubei, China
China Hunan, China
China Jiangsu, China
China Jiangxi, China
China Liaoning, China
China Shaanxi, China
China Shandong, China
China Shanghai, China
China Shanxi, China
China Sichuan, China
China Tianjin, China
China Xinjiang, China
China Zhejiang, China
China, Beijing Beijing, China
China, Sichuan Chongqing, Sichuan, China